WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability Corrigendum in /10.3892/ol.2018.8757

Zhang,Minghui; Dominguez,Donye; Chen,Siqi; Fan,Jie; Qin,Lei; Long,Alan; Li,Xia; Zhang,Yi; Shi,Huirong; Zhang,Bin

doi:10.3892/ol.2017.6584

WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability

Corrigendum in: /10.3892/ol.2018.8757

Authors:
- Minghui Zhang
- Donye Dominguez
- Siqi Chen
- Jie Fan
- Lei Qin
- Alan Long
- Xia Li
- Yi Zhang
- Huirong Shi
- Bin Zhang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Robert H. Lurie Comprehensive Cancer Center, Department of Medicine, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA, Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: July 15, 2017 https://doi.org/10.3892/ol.2017.6584
Pages: 3580-3586
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Wee1-like protein kinase (WEE1) physiologically serves a key function in maintaining the integrity of the cell genome through mediating the activation of cyclin-dependent kinase (CDK)1 and CDK2. Increased expression of WEE1 has been associated with the poor prognosis of patients with ovarian cancer. The present study aimed at examining the in vitro and in vivo antitumor activity of MK1775, a potent pharmacological inhibitor of WEE1, as a single agent against ovarian cancer cells. The cytotoxicity of MK1775 was examined in a panel of tumor cells using MTT in vitro. Subsequently, a cell apoptosis assay was performed in ovarian cancer SKOV3 and ID8 cells to characterize the function of MK1775 in tumor cell apoptosis, under either wild-type tumor protein 53 (p53) or null p53 status. In addition, cell cycle analysis and a western blot analysis were performed to validate the effect of MK1775 on cell cycle progression and to elucidate the underlying molecular mechanism of cell death. Finally, the in vivo antitumor efficacy of MK1775 as a single agent at a clinical well-tolerated dose was determined. A dose-dependent inhibitory effect of MK1775 on tumor cell viability was determined in distinct cell lines, including B16F10, LLC1, BPS1, EG7, ID8 and SKOV3. Results from the cell cycle analysis and western blotting indicated that MK1775 abrogated the G2/M checkpoint through inhibiting the phosphorylation of CDK1 and inducing the apoptosis of ovarian cancer cells that lacked mutations in p53 and breast cancer 1 (BRCA1). Additionally, a significant antitumor effect of MK1775 was observed in C57BL/6 mice bearing syngeneic ID8 ovarian tumors. The results of the present study supported the use of MK1775 as a monotherapy agent in ovarian cancer. MK1775 was effective at inducing mitotic catastrophe, independent of p53 and BRCA1 mutations. Therefore, WEE1 inhibition by MK1775 requires additional investigation to identify novel combination approaches in ovarian cancer therapy with the current DNA damaging agents, including irradiation treatment and cell cycle checkpoint inhibitors.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
3	Parker LL and Piwnica-Worms H: Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science. 257:1955–1957. 1992. View Article : Google Scholar : PubMed/NCBI
4	Watanabe N, Broome M and Hunter T: Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J. 14:1878–1891. 1995.PubMed/NCBI
5	McGowan CH and Russell P: Cell cycle regulation of human WEE1. EMBO J. 14:2166–2175. 1995.PubMed/NCBI
6	Nigg EA: Cyclin-dependent protein kinases: Key regulators of the eukaryotic cell cycle. Bioessays. 17:471–480. 1995. View Article : Google Scholar : PubMed/NCBI
7	Edgar BA and Lehner CF: Developmental control of cell cycle regulators: A flys perspective. Science. 274:1646–1652. 1996. View Article : Google Scholar : PubMed/NCBI
8	Magnussen GI, Holm R, Emilsen E, Rosnes AK, Slipicevic A and Flørenes VA: High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: Potential for targeted therapy. PLoS One. 7:e382542012. View Article : Google Scholar : PubMed/NCBI
9	Magnussen GI, Hellesylt E, Nesland JM, Trope CG, Flørenes VA and Holm R: High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients. BMC Cancer. 13:2882013. View Article : Google Scholar : PubMed/NCBI
10	Mir SE, De Witt Hamer PC, Krawczyk PM, Balaj L, Claes A, Niers JM, Van Tilborg AA, Zwinderman AH, Geerts D, Kaspers GJ, et al: In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell. 18:244–257. 2010. View Article : Google Scholar : PubMed/NCBI
11	PosthumaDeBoer J, Wördinger T, Graat HC, van Beusechem VW, Helder MN, van Royen BJ and Kaspers GJ: WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer. 11:1562011. View Article : Google Scholar : PubMed/NCBI
12	Iorns E, Lord CJ, Grigoriadis A, McDonald S, Fenwick K, Mackay A, Mein CA, Natrajan R, Savage K, Tamber N, et al: Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One. 4:e51202009. View Article : Google Scholar : PubMed/NCBI
13	Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B and Flørenes VA: Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. Gynecol Oncol. 135:118–124. 2014. View Article : Google Scholar : PubMed/NCBI
14	Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, Kimura T, Kaneko N, Ohtani J, Yamanaka K, et al: Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 8:2992–3000. 2009. View Article : Google Scholar : PubMed/NCBI
15	Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, Molkentine JM, Mason KA and Meyn RE: MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res. 17:5638–5648. 2011. View Article : Google Scholar : PubMed/NCBI
16	Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, Shumway SD, Mizuarai S, Hirai H, Maitra A and Hidalgo M: MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res. 17:2799–2806. 2011. View Article : Google Scholar : PubMed/NCBI
17	Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, Imagaki K, Ohtani J, Sakai T, Yoshizumi T, et al: MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther. 9:514–522. 2010. View Article : Google Scholar : PubMed/NCBI
18	http://clinicaltrials.gov/show/NCT01357161Accessed. 11 23–2013.
19	Mueller S, Hashizume R, Yang X, Kolkowitz I, Olow AK, Phillips J, Smirnov I, Tom MW, Prados MD, James CD, et al: Targeting Wee1 for the treatment of pediatric high-grade gliomas. Neuro Oncol. 16:352–360. 2014. View Article : Google Scholar : PubMed/NCBI
20	Guertin AD, Li J, Liu Y, Hurd MS, Schuller AG, Long B, Hirsch HA, Feldman I, Benita Y, Toniatti C, et al: Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Mol Cancer Ther. 12:1442–1452. 2013. View Article : Google Scholar : PubMed/NCBI
21	Harris PS, Venkataraman S, Alimova I, Birks DK, Balakrishnan I, Cristiano B, Donson AM, Dubuc AM, Taylor MD, Foreman NK, et al: Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. Mol Cancer. 13:722014. View Article : Google Scholar : PubMed/NCBI
22	Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M and Altiok S: MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther. 11:174–182. 2012. View Article : Google Scholar : PubMed/NCBI
23	Carrassa L, Chilà R, Lupi M, Ricci F, Celenza C, Mazzoletti M, Broggini M and Damia G: Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle. 11:2507–2517. 2012. View Article : Google Scholar : PubMed/NCBI
24	Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, Shin T, Curiel TJ and Zhang B: CD73 on tumor cells impairs antitumor T-cell responses: A novel mechanism of tumor-induced immune suppression. Cancer Res. 70:2245–2255. 2010. View Article : Google Scholar : PubMed/NCBI
25	Dominguez D, Ye C, Geng Z, Chen S, Fan J, Qin L, Long A, Wang L, Zhang Z, Zhang Y, et al: Exogenous IL-33 restores dendritic cell activation and maturation in established cancer. J Immunol. 198:1365–1375. 2017. View Article : Google Scholar : PubMed/NCBI
26	Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, You MJ, DePinho RA, McMahon M and Bosenberg M: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 41:544–552. 2009. View Article : Google Scholar : PubMed/NCBI
27	Hooijkaas AI, Gadiot J, van der Valk M, Mooi WJ and Blank CU: Targeting BRAFV600E in an inducible murine model of melanoma. Am J Pathol. 181:785–794. 2012. View Article : Google Scholar : PubMed/NCBI
28	Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P and Porter CC: Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol Cancer Ther. 12:2675–2684. 2013. View Article : Google Scholar : PubMed/NCBI
29	Lim ST, Miller NL, Nam JO, Chen XL, Lim Y and Schlaepfer DD: Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival. J Biol Chem. 285:1743–1753. 2010. View Article : Google Scholar : PubMed/NCBI
30	Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, et al: Type-specific cell line models for type-specific ovarian cancer research. PLoS One. 8:e721622013. View Article : Google Scholar : PubMed/NCBI
31	Do K, Doroshow JH and Kummar S: Wee1 kinase as a target for cancer therapy. Cell Cycle. 12:3159–3164. 2013. View Article : Google Scholar : PubMed/NCBI
32	Gu L, Zheng H, Murray SA, Ying H and Jim Xiao ZX: Deregulation of Cdc2 kinase induces caspase-3 activation and apoptosis. Biochem Biophys Res Commun. 302:384–391. 2003. View Article : Google Scholar : PubMed/NCBI
33	Targeting p53 mutant ovarian cancer: Phase I result of the WEE1 inhibitor MK-1775 with carboplatin plus paclitaxel in patients (pts) with platinum-sensitive, p53-mutant ovarian cancer (OC). 45th Annual Meeting of the American Society of Clinical Oncology, Meeting Library. http://meeting library.asco.org2013.
34	http://clinicaltrials.gov/show/NCT01164995Accessed. November 23–2013.
35	Bucher N and Britten CD: G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer. 98:523–528. 2008. View Article : Google Scholar : PubMed/NCBI
36	Kawabe T: G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther. 3:513–519. 2004.PubMed/NCBI
37	Vance S, Liu E, Zhao L, Parsels JD, Parsels LA, Brown JL, Maybaum J, Lawrence TS and Morgan MA: Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle. 10:4321–4329. 2011. View Article : Google Scholar : PubMed/NCBI
38	Chilà R, Basana A, Lupi M, Guffanti F, Gaudio E, Rinaldi A, Cascione L, Restelli V, Tarantelli C, Bertoni F, et al: Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. Oncotarget. 6:3394–3408. 2015. View Article : Google Scholar : PubMed/NCBI
39	Magnussen GI, Emilsen E, Giller Fleten K, Engesæter B, Nähse-Kumpf V, Fjær R, Slipicevic A and Flørenes VA: Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma. BMC Cancer. 15:4622015. View Article : Google Scholar : PubMed/NCBI
40	Huang J, Wang L, Cong Z, Amoozgar Z, Kiner E, Xing D, Orsulic S, Matulonis U and Goldberg MS: The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(−/−) murine model of ovarian cancer. Biochem Biophys Res Commun. 463:551–556. 2015. View Article : Google Scholar : PubMed/NCBI
41	Quinn JE, Carser JE, James CR, Kennedy RD and Harkin DP: BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol. 113:134–142. 2009. View Article : Google Scholar : PubMed/NCBI